Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5127]

Targeting agent enfortumab vedotin a novel treatment for patients with advanced...

Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA

Targeting agent enfortumab vedotin a novel treatment for patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )

New agent targeting Nectin-4 produces responses in nearly half of patients with...

Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA

New agent targeting Nectin-4 produces responses in nearly half of patients with advanced urothelial cancer ( Prof Daniel Petrylak - Yale Cancer Center, New Haven, USA )

No difference in survival between laparoscopic surgery and open surgery in...

Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway

No difference in survival between laparoscopic surgery and open surgery in colorectal cancer patients with liver metastases ( Dr Åsmund Fretland - Oslo University Hospital, Oslo, Norway )

Novel therapies in the treatment of bladder cancer

Dr Petros Grivas and Dr Andrea Necchi

Novel therapies in the treatment of bladder cancer ( Dr Petros Grivas and Dr Andrea Necchi )

Update on CARMENA trial: Cytoreductive nephrectomy in metastatic renal cancer...

Prof Arnaud Mejean - Paris Descartes University, Paris, France

Update on CARMENA trial: Cytoreductive nephrectomy in metastatic renal cancer with focus on intermediate IMDC-risk population ( Prof Arnaud Mejean - Paris Descartes University, Paris, France )

PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA...

Dr Hedy Kindler - University of Chicago, Chicago, USA

PARP inhibitor olaparib as treatment for pancreatic cancer patients with BRCA gene mutations ( Dr Hedy Kindler - University of Chicago, Chicago, USA )

Enzalutamide as treatment for men with mHSPC who have received testosterone...

Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA

Enzalutamide as treatment for men with mHSPC who have received testosterone suppression ( Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA )

Enzalutamide improves survival for men with metastatic hormone-sensitive...

Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA

Enzalutamide improves survival for men with metastatic hormone-sensitive prostate cancer ( Dr Christopher Sweeney - Dana-Farber Cancer Institute, Boston, USA )

Comment: Using enzalutamide will allow patients to avoid chemotherapy and...

Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, USA

Comment: Using enzalutamide will allow patients to avoid chemotherapy and steroids improving quality of life ( Dr Neeraj Agarwal - Huntsman Cancer Institute, Salt Lake City, USA )

Maintenance therapy with PARP inhibitor olaparib delays progression in patients...

Dr Hedy Kindler - University of Chicago, Chicago, USA

Maintenance therapy with PARP inhibitor olaparib delays progression in patients with BRCA-related pancreatic cancer ( Dr Hedy Kindler - University of Chicago, Chicago, USA )

Comment: It is essential to identify the BRCA gene in pancreatic cancer...

Dr Suzanne Cole - UT Southwestern Medical Center, Dallas, USA

Comment: It is essential to identify the BRCA gene in pancreatic cancer patients allowing them to be treated with an oral agent ( Dr Suzanne Cole - UT Southwestern Medical Center, Dallas, USA )

Clinical and translational results from the NEOSTAR study: Treating early-stage...

Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston...

Clinical and translational results from the NEOSTAR study: Treating early-stage lung cancer with nivolumab plus ipilimumab ( Dr Tina Cascone - The University of Texas MD Anderson Cancer Center, Houston, USA )

More from ecancer